The raised guidance and positive Phase 3 ReSPECT data create a strong catalyst path. Monitor the sNDA submission timeline for REZZAYO prophylaxis (expected H2 2026) and the TDAPA expiration impact on DefenCath pricing. The $75M share repurchase authorization provides downside support. Key risk: the $9.0M favorable adjustment is non-recurring, and DefenCath growth trajectory without it needs assessment.
CRMD drugs
CRMD drug pipeline →Price Chart
Executive Summary
CorMedix reported Q1 2026 revenue of $127.4M and GAAP net income of $38.6M ($0.43 diluted EPS), with DefenCath sales of $97.5M and Melinta portfolio contributing $29.9M. The company raised full-year 2026 revenue guidance to $325-345M and adjusted EBITDA guidance to $115-135M, citing strong DefenCath utilization and positive Phase 3 ReSPECT data for REZZAYO prophylaxis. The quarter included a non-recurring $9.0M favorable sales allowance adjustment, and the YoY revenue comparison is distorted by the August 2025 Melinta acquisition.
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $127.4M vs $39.1M in Q1 2025 (226% YoY growth, largely acquisition-driven)
- GAAP net income $38.6M ($0.43 diluted EPS) vs $20.6M ($0.30 diluted EPS) in Q1 2025
- Adjusted EBITDA $70.0M vs $23.6M in Q1 2025
- DefenCath sales $97.5M (includes $9.0M non-recurring favorable sales allowance adjustment)
- Melinta portfolio contributed $29.9M in Q1 2026 (first full quarter of combined operations)
- Raised FY 2026 revenue guidance to $325-345M (from $300-320M) and adjusted EBITDA to $115-135M (from $100-125M)
- Positive Phase 3 ReSPECT topline results for REZZAYO prophylaxis announced April 27, 2026; sNDA submission expected H2 2026
- Cash and short-term investments $178.1M at March 31, 2026, up from $148.5M at December 31, 2025
- Operating cash flow $42.4M in Q1 2026 vs $19.7M in Q1 2025
Financial Impact
Revenue guidance raised by $25M at midpoint ($335M vs prior $310M); adjusted EBITDA guidance raised by $12.5M at midpoint ($125M vs prior $112.5M)
Risk Factors
- Pending TDAPA expiration could pressure DefenCath reimbursement and revenue
- Non-recurring $9.0M favorable sales allowance adjustment inflated Q1 DefenCath revenue
- Melinta portfolio integration and anti-infective market competition
- REZZAYO sNDA regulatory risk and commercial launch timing (target 2027)
- Dilution from 92.985M diluted shares vs 68.975M in Q1 2025 (35% increase from Melinta acquisition)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001410098-26-000020 |
| Document: crmd-20260514.htm | 0001410098-26-000020 |
| Document: 0001410098-26-000020-index-headers.html | 0001410098-26-000020 |
| Document: 0001410098-26-000020-index.html | 0001410098-26-000020 |
| Document: 0001410098-26-000020.txt | 0001410098-26-000020 |
| 8-K Data (Synthetic) | 0001410098-26-000020 |
Track record
21 reports on CRMD
9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers